Gain insight into factors determining treatment appropriateness in high-risk non-metastatic #ProstateCancer 📌Check out our new case-based #CME course: ppcp.mirrorsmed.org/en/topic/pzo0k… 📽️ Including 2 cases with a video discussion by Johan Stranne Vérane Achard OncoAlert

#clinicalresearch #prostatecancer #genitourinarydisease

📌Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials: ✴️3604 patients ☢️Radiotherapy + long term ADT ❗️Gleason score ≥8 ; cN1; cT3–4; and PSA >20 ng/ml were associated with poorer outcomes!! ‼️Pts with two to

🚨Risk Stratification of Patients with Recurrence After Primary Treatment for #ProstateCancer🚨 European Urology ✍️Systematic Review of prospective data 👉Recurrence after PCa tx can be difficult to prognosticate Risk factors w/ at least moderate evidence include:

It's time to revisit the importance of estrogens in men...academic.oup.com/jes/article/do…

All Biochemical Recurrences Are Equal, but Some Are More Equal than Others sciencedirect.com/science/articl… A honor to comment on the superb review by Adam B. Weiner, MD Vérane Achard European Urology

tombal discussing the Key point to consider a de-escalation strategy in mCSPC! 👉 Why! Who! How ! When!! GUARD Consortium Asociación Argentina de Oncología Clínica (AAOC) #GUARDSymposium2024 Piet Ost Advanced Prostate Cancer Consensus Conference silke gillessen David Olmos Dra. María Natalia Gandur Quiroga Elena Castro

Day One of #GUARDSymposium2024 🚨 tombal 🇧🇪 Discussing: Have we reached a plateau in treatment intensification in mHSPC?: The role of de- escalation strategies GUARD Consortium 🇪🇸

#GUARDSymposium2024 Amazing talk by tombal about de-escalation of systemic treatment in advanced PCa: ➡️How? ➡️Who? ➡️When? OncoAlert OncoReporte Ana Paula Garcia Cardoso David Muniz David Muniz Marcelo Wroclawski Stephen Freedland, MD #OncoAlert #OncoReporte

Darolutamide outcomes in #European patients with #mHSPC from the #ARASENS trial. tombal UCLouvain joins Alicia Morgans, MD, MPH Dana-Farber in this discussion on UroToday > bit.ly/4aODZfQ

Is There a Place for De-escalating Therapy in Patients with Metastatic... sciencedirect.com/science/articl…

Is There a Place for De-escalating Therapy in Patients with Metastatic...The answer is clinical trials.... silke gillessen Fabio Turco aurelius omlin Advanced Prostate Cancer Consensus Conference EORTC GUCG YI EORTC sciencedirect.com/science/articl…

Hot topic discussed by tombal And silke gillessen AT Getug research days

EORTC is pleased to announce that the primary endpoint has been reached in the EORTC-1333-GUCG/PEACE III Trial. eortc.org/blog/2024/07/1… silke gillessen tombal Unicancer CancerTrialsIreland 🌈 LACOG - Latin American Cooperative Oncology Group Canadian Urological Association

Stellar talk by Paulo G Bergerot on exercise in oncology for patients with renal cell carcinoma ANZUP #ANZUP24 This program has significantly improved patients’ quality of life and mitigated symptom burden

Darolutamide outcomes in #European patients with #mHSPC from the #ARASENS trial. tombal UCLouvain joins Alicia Morgans, MD, MPH Dana-Farber in this discussion on UroToday > bit.ly/4aODZfQ

The endless debate in patients with BCR after radical treatment: Do Not EMBARK on When, If the Answer Is How | Journal of Clinical Oncology . ascopubs.org/doi/10.1200/JC… Gianluca Giannarini

tombal Gianluca Giannarini Thanks for keeping the debate alive! Let us question the When as well as the How. BCR is a tough space that deserves its own designs and endpoints, and a nuanced approach with patients. Ravi A Madan M.D. ascopubs.org/doi/10.1200/JC…

#PACE A published in European Urology! SBRT vs Radical prostatectomy. Spread the word #SBRT should be discussed with eligible patients ⁦Dr Shaun Tolan⁩ Alison Tree 💙⁩ ⁦Clive Peedell⁩ Dr. Andrew Loblaw⁩ ⁦Prof Emma Hall⁩ Prof Joe O'Sullivan⁩ authors.elsevier.com/sd/article/S03…

Late Breaking Results from the EORTC 1333/PEACE III phase III trial at #ESMO24 eortc.org/blog/2024/09/1… Gustave Roussy Unicancer tombal GETUG; LACOG - Latin American Cooperative Oncology Group; silke gillessen #CancerResearch #ClinicalTrials #Oncology